Skip to main content
main-content

Diabetes complications and comorbidities: Nephropathy

Expert opinion editorial

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

Ask the expert video

Team-based care for patients with type 2 diabetes and kidney disease

Team-based care for patients with type 2 diabetes and kidney disease

WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).

Get more on: Nephropathy | Diabetes complications and comorbidities | Ask the expert videos

medwireNews top story

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Pills in hand

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

Interactive patient case study

Renal complications in diabetic ketoacidosis

Renal complications in diabetic ketoacidosis

This 15-minute case presents likely causes of renal complications in diabetic ketoacidosis and explains how to identify the signs and symptoms of renal complications to ensure early initiation of appropriate treatment.

Get more on: Diabetic ketoacidosis | Pediatric diabetes | Nephropathy

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

Ask the expert video

Diabetic kidney disease: A call to primary care

Diabetic kidney disease: A call to primary care

Nephrologist and Endocrinologist Katherine Tuttle joins Primary Care Physician Jay Shubrook to discuss the importance of kidney disease screening for the prevention of downstream nephropathy and cardiovascular disease in patients with diabetes [watch the video 8:16].

Get more on: Nephropathy | Diabetes complications and comorbidities

medwireNews editor's pick

Real-world bariatric surgery data show microvascular protection

Surgical tools

Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.

Journal article

Chronic kidney disease-induced insulin resistance: Current state of the field

Kidneys and urinary bladder (illustration)

This review will evaluate mechanisms responsible for chronic kidney disease-induced insulin resistance and therapies currently available [read more].
Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

Get more on:  Diabetic complications | Type 1 diabetes | Type 2 diabetes

Journal article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Smiling doctors

We present one successful case that demonstrates a significantly beneficial effect of physical exercise and lifestyle intervention in the management of type 2 diabetes mellitus [read more].
Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

Get more on: Type 2 diabetes | Physical activity | Lifestyle interventions​​​​​​​

medwireNews

09-20-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

09-09-2019 | Nephropathy | News

Meta-analysis supports use of SGLT2 inhibitors to prevent kidney failure

Findings from a systematic review and meta-analysis suggest that SGLT2 inhibitors reduce the risk for major adverse kidney outcomes among people with type 2 diabetes, regardless of baseline kidney function.

09-03-2019 | Retinopathy | News

Microvascular benefits of lowest HbA1c target in type 1 diabetes questioned

Aiming for the lowest international targets in glycated hemoglobin levels may not protect against retinopathy and nephropathy in patients with type 1 diabetes, research suggests.

Interactive patient case study

12-21-2018 | Ketoacidosis | Case study | Link

Renal complications in diabetic ketoacidosis

Develop and test your knowledge on the renal complications associated with diabetic ketoacidosis through this practical example and self-assessment authored by Professor Francesco Chiarelli. This 15-minute case presents likely causes of renal complications in diabetic ketoacidosis and explains how to identify the signs and symptoms of renal complications to ensure early initiation of appropriate treatment.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-23-2018 | Complications | Article

Validation of time in range as an outcome measure for diabetes clinical trials

Beck RW et al. Diabetes Care 2018: dc181444. doi: 10.2337/dc18-1444

09-08-2018 | Nephropathy | Review | Article

Metabolic abnormalities in diabetes and kidney disease: Role of uremic toxins

Koppe L, Fouque D, Soulage CO. Curr Diab Rep 2018; 18: 97. doi: 10.1007/s11892-018-1064-7

08-15-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits